Health
Final Results from REPRISE III: Long-Term Stroke Risk after TAVR for Severe Aortic Stenosis – DocWire News
A study presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2021 Annual Meeting reported the final five-year results…
A study presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2021 Annual Meeting reported the final five-year results from the REPRISE III randomized trial, which assessed the Lotus Valve transcatheter aortic valve replacement (TAVR) system…
Continue Reading
-
Business19 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News18 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
Noosa News15 hours agoTips to improve engagement – Proctor
-
General13 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline